Ahmed Saadeddin, MD, FRCR, of the King Saud Bin AbdulAziz University for Health Sciences, Riyadh, Saudi Arabia, addresses the challenges associated with sequencing treatments for HR+ breast cancer patients. Dr Saadeddin raises questions that are yet to be answered surrounding determining the best treatment strategies for patients when a variety of different combination and monotherapies are becoming more available. Can fulvestrant be effective as a monotherapy? And when should combination therapy be considered in the treatment course? This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.